Keros Therapeutics

LEXINGTON, MA · Founded 2015 · Biotech · Public

Small molecule therapeutics for hematological, pulmonary, and cardiovascular diseases

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · kerostx.com

Sector
Biotech
Headquarters
LEXINGTON, MA
Founded
2015
Latest Form D
$56M, Mar 2020
Total capital
$70.8M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$70.8M
3 Form D · last Mar 2020
80 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
18
22 pending · first 2021
Rank in peer group#94 of 1449

Capital timeline

20162017201820192020FEDERAL ↑EQUITY ↓Cumulative $70.8M1st Form D$3.3M2nd Form D$11.5M3rd Form D$56M
20162017201820192020FEDERAL ↑EQUITY ↓Cumulative $70.8M1st Form D$3.3M2nd Form D$11.5M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$56M
  • Private capital raisedForm D · SEC · 2nd filing$11.5M
  • Private capital raisedForm D · SEC · 1st filing$3.3M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#94 · top 6%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Jasbir S. SeehraResearcherExecutive Officer, DirectorLinked by 1 patent
  • Alon S. LazarusDirectorNamed in SEC Form D filings
  • Carl GordonDirectorNamed in SEC Form D filings
  • Claudia OrdonezExecutive OfficerNamed in SEC Form D filings
  • Jenn LacheyExecutive OfficerNamed in SEC Form D filings
  • Julius S. KnowlesDirectorNamed in SEC Form D filings
Show all 11 people
  • Keith RegnanteExecutive OfficerNamed in SEC Form D filings
  • Nima FarzanDirectorNamed in SEC Form D filings
  • Ohad S. HammerDirectorNamed in SEC Form D filings
  • Ran NussbaumDirectorNamed in SEC Form D filings
  • Zafrira S. AvnurDirectorNamed in SEC Form D filings

What it has protected

USPTO · 18 granted of 40
  • New patentMethods Of Treating Cardiovascular-related DiseaseUSPTOUS 12,766,147
  • PendingMethods Of Treating Iron OverloadUSPTOApplication 19328461
  • PendingMethods Of Using Activin Receptor Type II VariantsUSPTOApplication 19390938
Show all 40 patent records

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .